Multiple Myeloma

Overview

Multiple myeloma is a cancer of plasma cells — white blood cells in the bone marrow that normally produce antibodies to fight infection. In myeloma, abnormal plasma cells multiply uncontrollably, crowd out normal blood cells, produce an abnormal antibody protein (a paraprotein), and release substances that weaken bones and can harm the kidneys.

Myeloma is generally a treatable but not currently curable cancer that is often managed as a long-term, relapsing and remitting condition. Modern drug combinations, and stem cell transplantation for suitable patients, can control the disease for years and relieve symptoms. Care is led by a haematologist within a multidisciplinary team.

This page is an educational overview only and is not medical advice. Diagnosis and treatment must be arranged with a qualified haematology team, and no outcome can be guaranteed.

Who May Need This

Assessment for myeloma may be needed by people with unexplained bone pain or fractures, persistent tiredness from anaemia, recurrent infections, kidney problems, or a high blood calcium level. It is more common with increasing age and is sometimes discovered incidentally when blood or urine tests show an abnormal protein.

Some people are found to have earlier, non-cancerous conditions such as MGUS (monoclonal gammopathy of undetermined significance) or smouldering myeloma, which may only need monitoring. A haematologist determines whether treatment is required based on tests and symptoms.

When It May Be Recommended

Active treatment is generally recommended when myeloma is causing organ damage — the CRAB features of high calcium, kidney impairment, anaemia or bone disease — or when specific high-risk markers indicate a very high chance of progression. Earlier stages such as MGUS and low-risk smouldering myeloma are often carefully monitored rather than treated immediately.

The intensity and type of treatment depend on the person's age, fitness, kidney function and the disease features, including genetic changes in the myeloma cells. The decision, including whether to plan for a stem cell transplant, is made by the haematology team after full assessment.

Diagnosis and Evaluation

Diagnosis combines blood and urine tests for the abnormal protein (including serum free light chains and protein electrophoresis), a full blood count, and kidney and calcium levels. A bone marrow biopsy confirms the proportion of abnormal plasma cells and provides material for genetic (cytogenetic) testing that helps assess risk.

Imaging such as whole-body low-dose CT, MRI or PET-CT is used to look for bone damage. Together these results establish the diagnosis, stage and risk group, which guide treatment. A second opinion may be valuable given the number of treatment options and the long-term nature of the disease.

Treatment Options

First-line treatment usually combines several drug classes — proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies and steroids — given together over several cycles to control the disease. Fitter patients are often offered an autologous stem cell transplant to deepen and prolong the response, sometimes followed by maintenance treatment.

Supportive treatments are essential: bone-strengthening drugs (bisphosphonates or denosumab), management of anaemia and kidney problems, infection prevention, and radiotherapy or surgery for painful or unstable bone lesions. When myeloma relapses, different drug combinations, and in specialist centres newer antibody and cellular therapies such as CAR T-cell therapy, may be used.

How It Is Performed

Most myeloma treatment is delivered as drug therapy — a mix of tablets, injections under the skin and intravenous infusions — given in cycles over months, usually as an outpatient. Blood tests before each cycle monitor the response and side effects, and doses are adjusted to balance effectiveness and tolerability.

For an autologous stem cell transplant, the patient's own stem cells are collected from the blood after stimulation, stored, and later returned by drip after a high dose of chemotherapy has cleared the marrow. This intensive part of treatment requires a hospital stay of a few weeks with close monitoring while blood counts recover.

Preparation

Preparation includes completing staging tests, treating any kidney problems, high calcium or infection, and starting bone protection. Good dental care and up-to-date vaccinations help reduce complications. Your team reviews all medicines and explains the planned regimen and, if relevant, the transplant pathway.

If you are travelling for treatment, bring full records of your diagnosis, bone marrow and genetic results, and imaging. Because treatment runs over many cycles and any transplant needs weeks of monitoring, plan carefully which parts will be given abroad and which at home, and arrange safe continuation of care.

Benefits and Expected Goals

The goals of treatment are to control the myeloma, achieve and maintain remission, protect the bones and kidneys, relieve symptoms such as pain and tiredness, and preserve quality of life for as long as possible. Modern combinations and transplantation have substantially improved how long many people live well with myeloma.

Because myeloma tends to relapse, treatment is usually about long-term control rather than cure, and benefits vary widely between individuals. Your haematologist can explain realistic goals for your risk group and how the response is measured with blood tests over time.

Risks and Possible Complications

Both the disease and its treatment can cause complications that need active management.

• Infections from a weakened immune system, sometimes serious
• Bone pain, fractures and, rarely, spinal cord compression
• Kidney impairment and high blood calcium
• Anaemia, bleeding or clotting problems, and fatigue
• Drug side effects such as nerve tingling (neuropathy), bowel upset, and effects specific to each agent; transplant carries risks from intensive chemotherapy and low blood counts

Your team monitors for these and uses supportive care to prevent and treat them. Report fever, severe bone pain, reduced urine output, or new weakness or numbness urgently.

Recovery, Follow-up & Aftercare

Because myeloma is a long-term condition, "recovery" usually means reaching a stable remission with ongoing monitoring rather than a single endpoint. After intensive treatment such as a transplant, it can take weeks to months to regain energy and immune strength, with careful attention to infection risk during this time.

Follow-up includes regular blood tests to track the paraprotein and light chains, bone and kidney monitoring, and often maintenance treatment. If you were treated abroad, ensure your home haematology team has full records so long-term monitoring and any future relapse treatment are seamless.

Medical Tourism Planning

Myeloma care is delivered over the long term, so continuity matters as much as any single treatment. Choose a JCI- or ISO-accredited hospital with a specialist haematology service, transplant capability if needed, and strong supportive care. Confirm the full treatment plan, including which cycles or the transplant will be given abroad, in writing.

Decide clearly what will be done abroad versus at home, ensure both teams communicate, and plan an in-country stay to match — several weeks if a transplant is included. Arrange ongoing monitoring at home and consider medical travel insurance.

Estimated Cost Factors

Cost depends on the drug combination used (some agents are expensive), the number of cycles, whether a stem cell transplant is included, and supportive care such as bone protection, transfusions, imaging and management of complications. A transplant adds hospital stay and intensive monitoring costs.

Many destinations offer myeloma treatment and transplantation at a fraction of typical US prices, but costs vary widely and cannot be judged from online figures. Always request a personalized written quote covering the planned treatment and what is included before deciding.

Choosing a Hospital or Specialist

Look for a hospital with recognised accreditation, a dedicated haematology unit, transplant experience and accreditation if a transplant is planned, and strong infection-control and supportive-care services. Confirm the haematologist's experience with myeloma and access to modern drugs and, where relevant, cellular therapies.

Ask about international patient services, interpreter support, and how long-term monitoring and any relapse treatment would be coordinated with your home team. Written treatment and cost plans are signs of a quality programme.

Alternatives

For early disease such as MGUS or low-risk smouldering myeloma, active monitoring without treatment is often the appropriate choice. When treatment is needed, alternatives lie in the choice of drug combinations, whether to include a transplant, and, at relapse, newer therapies including antibody and cellular treatments, sometimes within clinical trials.

Supportive and palliative care — pain control, bone protection and symptom management — is important alongside any treatment. Each approach has different benefits and side effects. Discuss all options with your haematologist so the plan fits your disease and priorities.

Questions to Ask Your Doctor

• What stage and risk group is my myeloma, and does it need treating now?
• Which drug combination do you recommend, and how many cycles?
• Am I suitable for a stem cell transplant, and what would it involve?
• How will you protect my bones and kidneys and prevent infection?
• What side effects are likely, and what warning signs need urgent help?
• What are realistic goals of treatment for my situation?
• If I travel, which parts can be done abroad and which at home?
• What is included in the written cost estimate?